JAMA Pediatrics: Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratio
A recent cohort study conducted at Pennsylvania Hospital, Philadelphia involving 1714 participants assessed maternal and cord blood for the transfer of SARS-CoV-2 antibodies. Trial participants were from various ethnic backgrounds with ages ranging from 28-35 years. IgG and/or IgM was detected in 83 woman at the time of delivery and IgG was detected in the cord blood of 72 of the 83 infants. The transfer of antibodies occurred after symptomatic and asymptomatic infections during pregnancy.
To read the article in full refer to the link below:
December 2020 CVU recording is now available via our Education Portal
Our December CVU covered topics such as COVID-19 vaccines, influenza, vaccine safety and vaccine communication. A recording of this event is now available for viewing.
To access this recording please sign in to our Education Portal and follow the prompts.
Please note that if you have not visited our new Education Portal, you will need to sign up to access content.
MVEC eLearning: Use of Multi-Dose Vials
MVEC are excited to launch the next of our eLearning packages. Our eLearning packages are designed to allow immunisation providers consolidate and evaluate their technical skills. Targeted resources are available to assist with our eLearning and a certificate of completion will be made available upon completion of the corresponding eLearning quiz.
Use of Multi-Dose Vials has been designed to demonstrate the safe preparation and storage of vaccines from multi-dose vials that require reconstitution and from those that do not.
You can access Use of Multi-Dose Vials via our शिक्षा पोर्टल.
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b studies being conducted in South Africa.
The UK phase III clinical trial involves more than 15,000 participants aged 18-84 years. During a period of high transmission with the UK variant of SARS-CoV-2, the preliminary results show an efficacy rate of 89.3%. After review of the vaccine safety database it has also been reported that any adverse events were balanced between both the vaccine and the placebo groups and any serious or severe side effects occurred at low levels.
In the South African phase 2b clinical trial, an efficacy rate of 60% was seen in the HIV-negative cohort, with an overall 49.4% efficacy rate seen across the total 4,400 trial participants (both HIV-negative and HIV positive individuals). During the time of the trial, the South African variant of SARS-CoV-2 was widely circulating.
The Novavax COVID-19 vaccine candidate is a protein-based vaccine utilising a nanoparticle technology platform.
To read the full press release follow the link below:
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
New immunisation reference page: COVID-19 vaccines: frequently asked questions
MVEC's COVID-19 vaccine FAQ’s have been designed to address common queries relating to COVID-19 vaccines, and include information on the vaccine development process, priority groups, vaccine effectiveness, storage, administration and safety.
This page will be updated on a regular basis as further information becomes available.
MVEC: COVID-19 vaccines: frequently asked questions
New immunisation reference page: Vaccine-associated enhanced disease (VAED)
With hundreds of COVID-19 vaccine candidates in various stages of development and approval, an understanding of any potentially serious adverse events is vital to ensure vaccine acceptance and confidence.
Our new reference page explores vaccine-associated enhanced disease (VAED). It occurs when a more severe presentation of disease develops in an individual who has previously been immunised, compared with when an infection occurs without prior vaccination. VAED has previously been associated with dengue fever infection; RSV, MERS and SARS-CoV-1 vaccine candidates; as well as a measles virus.
It is a theoretical risk only when considering COVID-19 vaccine candidates however as a result, the possibility of VAED has been closely monitored during all stages of clinical trials for COVID-19 vaccine candidates.
For further information please refer to our reference page:
एमवीईसी: वैक्सीन से जुड़ी बढ़ी हुई बीमारी (वीएईडी)
टीजीए ने फाइजर कोविड-19 वैक्सीन को अस्थायी रूप से मंजूरी दे दी है
गहन और स्वतंत्र समीक्षा के बाद, चिकित्सीय सामान प्रशासन (टीजीए) ने पाया है कि फाइजर/बायोएनटेक कोविड-19 वैक्सीन उम्मीदवार, कॉमिरनाटी, अनंतिम अनुमोदन के लिए आवश्यक सख्त सुरक्षा और प्रभावकारिता मानकों को पूरा करता है। अब इसे कोविड-19 बीमारी की रोकथाम के लिए सक्रिय टीकाकरण के लिए 16 वर्ष या उससे अधिक उम्र के लोगों में उपयोग के लिए अस्थायी रूप से मंजूरी दे दी गई है।
अधिक जानकारी के लिए कृपया नीचे दिए गए लिंक देखें:
टीजीए ने फाइजर कोविड-19 वैक्सीन को अस्थायी रूप से मंजूरी दे दी है
COVID-19 vaccine: Pfizer Australia - COMIRNATY BNT162b2 (mRNA)
वैक्सीन अनुमोदन के अनंतिम मार्ग के बारे में अधिक जानकारी के लिए, कृपया नीचे हमारा संदर्भ पृष्ठ देखें:
एमवीईसी: ऑस्ट्रेलिया में सीओवीआईडी-19 वैक्सीन का अनंतिम पंजीकरण
TGA grants additional provisional determination for a COVID-19 vaccine
The Therapeutic Goods Administration (TGA) has granted provisional determination to Biocelect Pty Ltd (on behalf of Novavax Inc.) for their COVID-19 vaccine candidate.
Granting provisional determination means that Biocelect (on behalf of Novavax) is now eligible to apply for provisional registration. Following the provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data.
Provisional determination is only granted once the TGA has considered all eligibility criteria, including evidence of a plan to submit comprehensive clinical data.
You can read the press release from the TGA below:
TGA grants additional provisional determination for a COVID-19 vaccine
For more information on the process of COVID-19 vaccine provisional approval please refer to our reference page:
एमवीईसी: ऑस्ट्रेलिया में सीओवीआईडी-19 वैक्सीन का अनंतिम पंजीकरण
The Times of Israel: Israel expands vaccination campaign to teens aged 16-18
Israel have expanded their COVID-19 vaccination program to include teenagers aged ≥ 16 years, with the first vaccines being given in this age group on January 23.
Initial immunisation in Israel began in December 2020, prioritising health care workers, the elderly and other at-risk groups. To date, 2.5 million people have received a dose of the Pfizer BioNTech COVID-19 vaccine, with 900 thousand of those, also having received their second dose.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
The Times of Israel: Israel expands vaccination campaign to teens ages 16-18
COVAX announces new agreement, plans for first deliveries
The COVAX Facility has announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer/BioNTech COVID-19 vaccine.
COVAX is on track to deliver at least 2 billion doses of COVID-19 vaccines by the end of the 2021, including at least 1.3 billion doses to 92 lower income countries.
For more information please follow the link below:
Gavi: COVAX announces new agreement, plans for first deliveries